Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2016-06-16
• Target enrollment: 0
• Participant gender: All

Summary

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborators: Medical College of Wisconsin; Ohio State University; Optimum Therapeutics, LLC
• Treatments: Docetaxel; Suramin

Criteria

Inclusion Criteria:

• Pathologically proven diagnosis of non-small cell lung cancer

• Documented disease progression after first-line chemotherapy for non-small cell lung cancer

• Stable and treated CNS metastasis is allowed

• Radiation must be completed at least 2 weeks prior to starting protocol treatment

• Major surgery must be completed at least 4 weeks prior to starting protocol treatment

• ECOG performance status 0-2

• Sexually active patients must use adequate contraception

• Adequate bone marrow function

• Adequate renal function

• Adequate liver function

Exclusion Criteria:

• Severe hypersensitivity reaction to docetaxel

• Pre-existing grade 3 or 4 neuropathy

• Women who are pregnant or breastfeeding

• Uncontrolled intercurrent illness

• Receipt of 3 or more prior chemotherapy regimens